Form D · Biotechnology
TheoremDx Inc.
St. Paul, MN · CIK 0001751284
Offering snapshot reported Sep 11, 2018 · SEC filing
- Reported sold
- $793K Indefinite offering
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 2, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 11, 2018 | Initial | $793,446 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-321064
Source: Form D, filed Sep 11, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bruce Batten | Executive |
| John Coonan | Director, Executive |
| Kaye James Ehlen | Director, Executive |
| Stephanie James Griffin | Director, Executive |
| Frank Kiesner | Director |
| Michael Osterholm | Director |
| Mark Pearson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1431 Summit Ave.
St. Paul, MN, 55105
St. Paul, MN, 55105